Premium
Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
Author(s) -
Kuiper Roland P.,
Hoogeveen Patricia G.,
Bladergroen Reno,
Dijk Freerk,
Sonneveld Edwin,
Leeuwen Frank N.,
Boer Judith,
Sergeeva Irina,
Feitsma Harma,
Boer Monique L.,
Velden Vincent H. J.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17744
Subject(s) - minimal residual disease , fusion gene , polymerase chain reaction , risk stratification , immunoglobulin heavy chain , gene rearrangement , medicine , gene , antibody , disease , oncology , cancer research , immunology , biology , genetics , leukemia
Summary Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T‐cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.